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Background: The aim of this study was to discern whether a relation between biochemical parameters, sonogra-
phy and musculoskeletal data exists in cases of hyperthyroidism and whether they are modiﬁable through
supplementationwith selenomethionine andmagnesiumcitrate aswell as by acupuncture andmanualmedicine
methods.
Results:Adirect correlation betweenwhole blood seleniumand serummagnesiumwas found in subjectswithout
thyroid disease and inmenopausalwomenwhile itwas reversed in cases of thyroid diseases aswell as in patients
with depression, infection, and in infertile women. Vascularization indices were elevated in cases of newly diag-
nosed benign thyroid diseases.Musculoskeletal changes i.e. lateral tension and idiopathic moving toes, aswell as
situations of physical and psychological stress and minor trauma and infection led to an increase of vasculariza-
tion. Magnesium levels correlated negatively with these two conditions. The supplementation brought a reduc-
tion of the vascularization indices and reduced the incidence of idiopathic moving toes. Treatment of lateral
tension required manual medicine methods and acupuncture (gastrocnemius). A small subgroup of patients
showed a further reduction of hyper-vascularization after receiving coenzyme Q10.
Conclusions:We interpret the elevated thyroid vascularization and low magnesium levels as signs of an inﬂam-
matory process related to themusculoskeletal changes. Improvement of thyroid function andmorphology can be
achieved after correcting the inﬂuence of stressors together with the supplementation regime. We hypothesize
that the central biochemical event in thyroid disease is that of an acquired, altered mitochondrial function due
to deﬁciency of magnesium, selenium, and coenzyme Q10.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The pathogenesis of benign thyroid diseases is a question that has
puzzled medical science since the ﬁrst clinical and pathological
descriptions were made in the past centuries. Looking back into early
moments of clinical research one can ﬁnd the landmark descriptions
on hyperthyroidism that were published between 1825 and 1840 by
Parry, Graves, and von Basedow [1–3] while Hashimoto contributed
with the histological picture of goitrous lymphocytic thyroiditis in
1912 [4]. In 1906 McCarrison described the beneﬁcial use of iodine to
treat endemic goiter [5]. Later investigations have conﬁrmed the central
role of iodine in maintaining normal thyroid function [6]. Since the
1950s the conception of “autoimmunity” has stepped into the descrip-
tion of potential mechanisms that affect thyroid function. An account
of the development of this conception has been presented by Sawin.. This is an open access article underIn his opinion: “autoimmune thyroid disease is now itself a major
industry” (page 402 in [7]).
While iodine deﬁciency still prevails in some countries, benign thy-
roid disease is still being found in countries that have corrected this con-
dition. Thus it is sensible to consider that additional factors can be
involved in the pathogenesis of thyroid disease.
Since 2007we have been engaged in researchwork centered on thy-
roid function and thyroid disease. These investigations had a starting
point with patients presenting thyroid associated ophthalmopathy
(TAO) [8,9]. The key ﬁndings of these studies were the description of al-
terations of the musculoskeletal system including an inﬂammatory
reaction in the shanks together with axial displacement, e.g. lateral ten-
sion [10], eccentric muscle action, the idiopathic moving toes (IMT)
phenomenon, as well as an altered relationship between magnesium
and calcium. Investigating the micronutrient status of these patients
we found a high frequency of low levels of selenium in patients
presenting either hypothyroidism or hyperthyroidism [11]. At the
time this study on micronutrients was being carried out we started to
supplement thyroid disease patients only with selenomethionine [12].the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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data). In subsequent studies we have updated the reference values for
thyroid function tests for the local iodine-sufﬁcient population of
Austria in different age groups [13–15]. In the ﬁeld of sonography we
have recently adapted a quantitative 3-dimension power Doppler
method for the evaluation of thyroid vascularity [16]. This methodology
was originally developed for gynecological examinations by Pairleitner
et al. [17]. In 2014 we have been able to differentiate the clinical picture
of so-called psychosomatic symptoms from hypothyroidism and found
these symptoms to be directly associated with magnesium deﬁciency. In
situations of increasing physical and/or psychological stressors patients
show lower magnesium levels in blood [18]. In the discussion of
these ﬁndings we hypothesized that low magnesium levels would
alter the function of Complex V of oxidative phosphorylation knowing
that magnesium is the central player in ATP synthesis through the
F1FO-ATPase [19].
In this observational study we have now focused on patients with
hyperthyroidism and thyroiditis applying the previously described
methodology [18]. The merits of observational studies as stated by
Black [20] were kept in mind in designing this study. Based on the
frequent condition of low selenium and magnesium levels seen in
patients with benign thyroid diseases the null hypothesis of this obser-
vational study stated that administering selenomethionine and magne-
sium citrate would neither affect thyroid function, nor vascularity, nor
thyroid-associated symptoms. A second aim was to document thyroid
vascularity parameters in a variety of situations that included mainly
physical and psychological stressors and recording the changes
achieved after supplementation.2. Materials and methods
A consecutive series of 176 subjects, including 159 females, was in-
cluded between 2011 and 2013 in this observational study. The age of
the patients was 32.2 ± 11.1 years (mean ± S.D.), range 7 to 73 years.
All subjects were examined and treated at our private institution
(WOMED, Innsbruck, Austria). All procedures were done in accordance
with theDeclaration of Helsinki [21]. The term “TheWOMEDModel” re-
fers to a combination of examination, diagnostic and therapeutical
methods used routinely by us. This Model has been described and
explained recently in a publication where we dealt with the topic of
psychosomatics and hypothyroidism [18]. Data from this previous
study (patients with hypothyroidism) was also included in the present
one in order to compare them to hyperthyroidism.
The clinical examination was done as described before [8,10,18]
where a central role is played by methods used in Applied Kinesiology
(AK) [22–24]. An important addition to the previous approach is to
look for any pelvic fault associatedwith respiratory action [22]. Postural
changes that can be found through this examination include lateral ten-
sion and the idiopathic moving toes (IMT). Idiopathic moving toes are
shown on the video ﬁle.2.1. 3-D quantitative power Doppler thyroid sonography
The 3-dimensional quantitative power Doppler sonography of
the thyroid was done as described recently by us [16]. This examina-
tion delivers 3 parameters related to vascularization of the gland:
1) the vascularization index (VI) given as a percentagewhich reﬂects
the number or density of vessels within the volume being examined,
2) the ﬂow intensity of blood corpuscles during the 3D-sweep called
ﬂow index or FI, and 3) a combination of VI and FI which gives the
vascularization ﬂow index (VFI) thus reﬂecting a combination of
the vessel density and the number of blood corpuscles [25,26]).
Ultrasound studies were done twice, at the initial and at the
ﬁnal visit.2.2. Laboratory examinations
Thyroid function parameters, i.e. fT3, fT4 and TSH, as well as
magnesium levels were recorded for all patients. The determinations
were generally done at a local laboratory facility (Labor Philadelphy,
Innsbruck, Austria, http://www.phillab.at/). Results from another
laboratory which uses a similar methodology were also included.
“Third party” results were excluded, i.e. a new test was ordered. Since
not all thyroid antibody determinations came from the same laboratory,
the results were simply classiﬁed as being either negative or positive
according to the reference range of each method. Thyroid antibodies
were not determined in follow-up examinations. In a later phase of
the study we also included determinations of coenzyme Q10
(ubiquinone). We purposely chose these simple clinical chemistry
tests because they can be easily carried out at any laboratory.2.3. Stress evaluation
Based on the description made by Parry on the association of
stress and fright with thyroid disease [1] we evaluated the presence
of stressors in a simple declarative manner. The ﬁrst question
attempted to identify a previous traumatic situation in early life.
Modern research uses the terms prenatal maternal stress [27,28]
and early life stress [29,30] for these situations. The patients were
asked in simple language whether they had had psychological or
physical trauma as a child, care deprivation as a child, hospitalization
without parental company, or if the mother had gone through a
difﬁcult pregnancy. The next 2 questions explored current situations
such as daily hassles [31,32] (at home or at work) or feelings of
anxiety or fear, panic attacks, or irritability [33]. For subjects having
a score of 2 or 3 a stress reduction treatment was done as
described by us before [34]. Our original protocol has been extended
to include acupoints found along the Triple Burner Meridian (TB)
[18], i.e. acupoints located between TB4 (yáng chí) to TB8 (san
yang luo) [35]. Physical stress in the form of competitive sport
activity was also identiﬁed but was not included in the score. The
patients were also asked to observe and report any changes of
well-being and to recall if any slight traumatic events such as ankle
sprain had occurred in the past years.2.4. Linear regression studies for magnesium and selenium
Linear regression studies of magnesium and selenium levels were
done using a historical set of data which had already been analyzed
[11]. In this group of subjects selenium was measured in whole blood
samples; magnesium was measured both in whole blood as well as in
serum samples and compared to selenium levels. This set of patients
included 15 controls (10 females), 51 menopausal women, 15 patients
with thyroid disorders (14 females), 33 women with infertility, 17 pa-
tients with depression, and 25 patients with ﬂu-like light respiratory
infections.2.5. Supplementation procedure
Based on the results of our previous investigations, a daily nutritional
supplementation was designed to include selenomethionine (200 μg/d,
Pure Encapsulations©, pro medico Handels GmbH, Graz, Austria)
and a magistral formulation of magnesium citrate powder at a dose
of 3 × 1.4 mmol/day. The choice of magnesium citrate is based on
the beneﬁcial effects in energetics as shown by Siekmeyer et al. [36]
as well as on the positive effect on mitochondrial homeostasis [37].
Selenium was given daily for 4 weeks, afterwards only 3 times
per week. Magnesium supplementation was given over a period of
12 weeks.
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In a small series of 8 patients, body weight distribution was evaluat-
ed using a simple force plate system (Nintendo Wii) [38,39].
2.7. Statistical analysis
Statistical analysis was done by RM using IBM SPSS Statistics 21.
3. Results
3.1. Analysis of magnesium levels according to sonography and
laboratory results
Based on the results of the ultrasound examination as well as on the
thyroid function testswe classiﬁed48 subjects as havingbothnormal thy-
roid function tests as well as an uneventful morphology of the thyroid
(controls), 89 cases as hypothyroid, 24 cases as hyperthyroid, and 4
cases as presenting sub-acute thyroiditis. Patients already being treated
for thyroid dysfunction included 5 with hyperthyroidism, and 6 with
thyroiditis. Based on this classiﬁcation of thyroid function we found sig-
niﬁcant differences in the serum levels of magnesium, the highest levels
were seen in the control group (mean0.95±0.08mmol/l) and the lowest
in patients with hyperthyroidism (mean 0.72 ± 0.14 mmol/l, p b 0.001).
Fig. 1 depicts these differences.
3.2. Correlation studies for magnesium and selenium
The correlation analyses of whole blood selenium and bloodmagne-
sium levels in the historical group showed a positive correlation in
normal subjects as well as in menopausal women (Fig. 2, panels A–B).
An inverse situation, i.e. a negative correlation, was seen in cases of
infertility and in thyroid disorders (Fig. 2, panels C–D), in patients
with depression, and in patients with light respiratory tract infections
(data not depicted).
Interestingly, whole blood magnesium levels showed no correlation
with serum levels of magnesium. Classifying the results of the wholeFig. 1. Serum magnesium levels in the study groblood magnesium determinations given as mmol/l into low (27.41–
33.97), normal (34.02–36.00), and high (36.02–42.83) revealed the fol-
lowing ranges of serum levels of magnesium in mmol/l: 0.83–1.02,
0.86–1.00, and 0.60–1.00, respectively.
3.3. Analysis of the thyroid quantitative 3D-power Doppler sonography
The vascularization index (VI) given in %was found lowest in normal
subjects (mean 5.56 ± 2.9%). Patients with a sub-acute thyroiditis
presented initially high levels (mean 26.83 ± 16.6%) which dropped
signiﬁcantly after supplementation (mean 6.48 ± 1.8%). Patients with
hypothyroidism presented high levels as compared to the controls
(mean 15.41 ± 6.6%). The highest levels were seen in hyperthyroid pa-
tients (mean 42.29 ± 16.81%). Visual inspection of the 3D images
allowed us to recognize the presence of rather thick vessels within the
thyroid in some hyperthyroid patients having an elevated VI value. A
persisting elevation of VI was seen in some hyperthyroid patients. The
ﬂow index showed less variation among the groups studied, however
patients with hyperthyroidism as well as those with sub-acute thyroid-
itis had the highest values, i.e. 43.50 ± 5.14 and 41.78 ± 4.14, respec-
tively vs. 34.99 ± 2.70 in the control group. The Vascularization Flow
Index (VFI) showed the greatest differences among the groups. It was
highest in hyperthyroid patients as well as in sub-acute thyroiditis.
Hypothyroid patients as well as patients with treated thyroiditis
showed intermediate high values. The values in the control group as
well as in treated thyroiditis were similar (Fig. 3).
The 3D reconstruction of the power Doppler images (Fig. 4) clearly
shows the differences of vascularization intensity between a normal
control and an overt hyperthyroid case.
A cubic regression curve with negative slope depicts the association
between magnesium levels and the VFI values, i.e. low magnesium
levels were associated with high VFI values (Fig. 5).
3.4. Thyroid perfusion parameters and thyroid serology
All three thyroid perfusion parameters were lower in patients with
negative thyroid serology as compared to patients with positive thyroidups grouped according to thyroid function.
Fig. 2. The panel shows the differences in the regression analyses between whole blood selenium and blood magnesium levels. A: normals. B: menopausal women. C: thyroid disorders.
D: women with sterility. The measurement units are mg/l. Notice the change in the type of correlation in patients with thyroid disorders as well as in patient with sterility.
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VFI: 4.0 ± 2.8 vs. 10.5 ± 7.9). On the other hand, magnesium levels
were higher in patients with negative serology (0.88 ± 0.08 vs.
0.82 ± 0.11 mmol/l).
3.5. Thyroid perfusion parameters in relation to the stress score
The stress evaluation revealed a score of 1 in 27%, score of 2 in 40%,
and score of 3 in 33% of patients. The VFI was directly correlated to the
stress score such that the corresponding VFI values in stress scores 1
to 3 were 2.4 ± 1.6, 6.1 ± 5.1, and 11.2 ± 8.7, respectively. When the
subjects were classiﬁed primarily by their thyroid function status,
higher VFI levels were seen in hyperthyroid subjects and these values
were also related to the presence of lateral tension, IMT, and the stress
score. These relations are shown in Fig. 6A to B.
3.6. Inﬂuence of the supplementation procedure on TSH levels
In a group of 11 patients presenting elevated TSH levels although
thyroid morphology on ultrasound was normal we provided only mag-
nesium supplementation for 6 weeks. TSH levels dropped signiﬁcantly
(p = 0.022, paired t-test) afterwards. The observed TSH levels are
shown on Table 1. Based on our current laboratory criteria for theinterpretation of thyroid function tests [13,14] the patients presented
sub-clinical hypothyroidism at the initial examination. After supple-
mentation the TSH levels were within the normal range (p b 0.02).
Free T4 levels did not show a clear change tendency (p = 0.7).3.7. Presence of musculoskeletal changes in patients with thyroid disease and
effects of magnesium supplementation andmanual therapy and acupuncture
The results of the clinical examination revealed lateral tension in the
majority of patients presenting either hypothyroidism or hyperthyroid-
ism (more than 90% of cases). Among the patients with lateral tension
we found it to unilateral in 81.8%, and bilateral in 16.4% of cases. The
phenomenon of IMT was seen in a smaller number of subjects
(n = 46). In 60.4% of cases it was one-sided, in 31.25% of cases it was
two-sided, and ﬁnally a complex situation was seen in 2% of cases. A
complex situation means that IMT was elicited by rotation of the
hand. One-sided lateral tension was observed in 26 cases presenting
one-sided IMT, and in 12 cases presenting double-sided IMT. Bilateral
lateral tension was seen in 3 cases with one-sided IMT, as well as in 3
caseswith double-sided IMT. An example of IMT is shown in the accom-
panying video. The analysis of body weight distribution revealed a shift
of 2–3% to the side not affected by lateral tension.
Fig. 3. VFI values according to the clinical situation of thyroid disease.
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when single-sided lateral tension was found the VFI was 7.99 ± 6.91,
and when lateral tension was bilateral the VFI was 11.44 ± 8.5. On the
other hand the VFI levels showed no relation to IMT. The values found
were: 10.62 ± 7.75 in one-sided IMT, 8.41 ± 5.7 in two-sided IMT,
and 9.45 ± 2.86 in complex IMT situations. The opposite changes
were seen between lateral tension and IMT in relation to serummagne-
sium levels (Figs. 6A–B, 7A–B).
Fig. 7 A and B show the interrelations between IMT condition to
magnesium levels (A) and to VFI (B).
We obtained similar results when plotting the values of the simple
stress score and magnesium levels Fig. 8(A) as well as VFI, Fig. 8(B).
Magnesium supplementation led to a signiﬁcant drop in the propor-
tion of patients with IMT as this ﬁnding was no longer seen in 60% of
cases after 6 weeks. Correction of the respiratory faults of the pelvis
also diminished the amplitude of IMT movements. Lateral tension was
not affected by magnesium supplementation. Lateral tension was very
frequently seen in relation to anterior rotation of the hemi-pelvis of
the affected side. For the following procedures the patients were lying
supine on a treatment couch. These pelvic changes were corrected by
manual therapy procedures using De Jearnette blocks as described
elsewhere [22]. Treatment of lateral tension also required the use of
acupuncture. This was done using neutral needling technique and 0.25
× 25 mm acupuncture needles (Hwato Master Touch, Suzhou Medical
Appliance Factory, China provided by Bacopa, Austria). These individualFig. 4. 3-D reconstruction of a normal thyroid compareacupoints called A-shi [40] correspond to hardened structures on the
lateral side of the shank which was palpated during the foot rotation
test. Anatomically they correspond to the soleus and lateral portions
of the gastrocnemiusmuscles. Besides lateral tension and IMT, addition-
al changes found frequently were a blockade of the normal pelvic mo-
tion during the inspiratory phase of respiration [41]. This blockade
was treated with De Jearnette blocks in order to elevate the sacrum.
During these therapy sessions the patients reported some tingling sen-
sation on the shanks at the place where the acupuncture needles were
placed. After completing the 20–30-minute treatment session the pa-
tients described a sensation of having heavy shanks, warmth in the pel-
vis, as well as tiredness. Finally a feeling of general lightness was
reported when standing up.
3.8. Expanding the clinical picture via a-posteriori reconstruction
During the conduction of the study the patients were able to recon-
struct data on their prior clinical history and symptoms. At the begin-
ning the clinical symptoms included tachycardia, perspiration, muscle
tiredness, nervousness, being easily fatigued, diminished physical po-
tential, feeling unable to do sports due to unusual tiredness, muscle
cramps, stiffness of the muscles, and postural instability. Further items
included slight cognitive dysfunction being unable to concentrate,
memory loss, and “jumpy” thoughts. Some subjects reported also heat
sensation in the body and a sensibility towards a warm environment.d to the vascularity of a case of hyperthyroidism.
Fig. 5. Relationship between magnesium levels and the thyroid perfusion index VFI.
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skeletal changes and taking the supplementation. The patients reported
feeling ﬁtter, having more energy, showing less fatigue, having a better
sleep quality as well as correction of constipation. Single patients
described less anxiety and less panic feelings. After the patients had
been instructed about the nature of the musculoskeletal changes some
of them were able to recall potential predisposing factors. The most
frequent event could be identiﬁed as a situation of minor trauma in
the form of grade I ankle sprain with supination–extension of the foot
followed by a tendency to give-way. Such an event had occurred 5 to
8 years before, thus conﬁrming our previous index case description
[10]. These ankle sprain situations had required neither surgical care
nor immobilization. Some patients also recalled having injuries of the
sacrum while falling down backwards.
3.9. Sequential thyroid perfusion parameters in relation to hyperthyroid-
ism, physical stress, psychological stress, and common ﬂu
While themajority of patientswere examined three times, single se-
quential cases were followed closer and more often (up to 8 follow-up
examinations). This sequential follow up allowed us to recognize sever-
al conditions that showed an interactionwith the VFI parameter. The six
panels in Fig. 9 illustrate these interactions. The reader should keep in
mind that the data presented in these images are plotted individually
for each case andhave thus different Y-axis values. Fig. 9A andB demon-
strate the effect of physical stress in one trained and one untrained
subject, respectively, who competed in triathlon. The ﬁrst one showed
a slight increase post-competition after an Olympic distance triathlon
(1500 m swim, 40 K bike, 10 K run), however all values were always
in the normal range. The second subject competed in a sprint triathlon
(750 m swim, 20 K bike, 5 K run) without having sufﬁcient previous
physical training. The VFI increased signiﬁcantly after the competition
and remained elevated even 10 days post-competition. Fig. 9C shows a
case of incipient hypothyroidism immediately following IVF and embryo
transfer. The VFI increased to the upper range of normal and could be
stabilized by means of selenium and magnesium supplementation. Atthe same time TSH levels returned to the normal range. Fig. 9D depicts
the case of post-partum thyroiditis where the VFI was elevated.
Following supplementation a clear improvement was seen together
with normalization of thyroid function.
Fig. 9E depicts a period of 18 months of a patient who initially had
hyperthyroidism. The initial VFI was only slightly elevated. During
psychological stress due to a cumulative term examination (time
point 3) during medical studies the VFI increased and could be normal-
ized by supplementation. Later on a slight increase of the VFI was seen
after a small trauma to the armhad occurred as consequence of a bicycle
accident (time point 5). A second rebound was seen after the patient
started taking an oral contraceptive containing ethinyloestradiol and
chlormadinone (time point 8). After stopping the oral contraceptive
the VFI diminished (time point 9). Fig. 9F depicts the course of a female
patient with latent hypothyroidism that was treated solely with
selenomethionine and magnesium supplementation. Under this proto-
col both VFI and TSH decreased.
One case of a 26 year-old woman presenting Graves' disease was
followed during 3 years. Under the supplementation regimen a steady
improvement in thyroid function was observed. The most relevant
change seen in this case was the normalization of thyroid morphology
and perfusion as seen in ultrasound (Fig. 10). Parallel to these parenchy-
mal changes the size of the thyroid diminished signiﬁcantly. Surgery
was no longer considered as an option.
We had the unique opportunity to examine and treat three siblings,
all females, of which 2 were twins. Initially one of the twins was diag-
nosed as having Graves' disease. The second twin looked for medical
counseling in order to discard a similar affection, which was indeed
present. The clinical and laboratory ﬁndings of the twins were extraor-
dinarily similar during the whole course of treatment. Initially
magnesium levels were 0.6 mmol/l. Supplementation was started
with 8 tablets of a combinedmagnesium citrate plus glutamate prepara-
tion containing 60 mg elemental magnesium per tablet, i.e. This dose
corresponded to 6.85mgMg/kg BW totaling 19.74mmol/day. According
to Seelig an adult requires between 5 and 10 mg magnesium per
kilogram [42]. This strategy showed very modest clinical improvement.
Fig. 6. Reciprocal changes of magnesium levels and VFI in relation to ﬁndings of lateral
tension.
Fig. 7. Reciprocal changes of magnesium levels and VFI in relation to ﬁndings of idiopathic
moving toes.
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citrate, 1.4 mmol/capsule t.i.d. Although magnesium levels did not in-
crease under this dose thyroid hormone levels decreased by 20%. The
third sibling was seen also in order to discard thyroid disease. At the
time of presentation an ophthalmologic problem was present in the
form of Leber hereditary optic neuropathy. Upon clinical examination
we found similar postural changes as we have described in thyroid asso-
ciated ophthalmopathy [8]. Her symptoms improved after correction of
the postural changes together with a combined supplementation planTable 1
Changes in TSH and fT4 levels given in μU/ml after exclusive supplementation with magnesium
TSH t0 4 4.6 3.9 8.1 5.7 2.3
TSH t1 2.1 3.2 1.6 3.47 1.5 1.6
fT4 t0 15.1 18.3 16.1 15.6 18.6 18.4
fT4 t1 15.4 14.8 14.4 11.6 16.7 15.3with magnesium citrate, selenomethionine and coenzyme Q10. In view
of these results, coenzyme Q10 (120 mg/capsule, Pure Encapsulations)
was also added to the supplementation of the twins. This triple approach
brought a normalization of thyroid function together with an improve-
ment in the morphology of thyroid vascularity (Fig. 11). It should be
noted that the initialmorphology of the vesselswhich appeared as thick-
ened structures was no longer present at the end.
Finally one patient was studied during the beginning of a viral affec-
tion (common ﬂu) which began short time after a routine medicalcitrate at a dose of 3 × 1.4 mmol/d.
mean ± S.D.
6.1 6.3 21 17.3 5.1 7.6 ± 5.9
3.1 3 4 3.1 2.7 2.67 ± 0.8
10.9 9.1 8.8 10.4 13.4 14.06 ± 3.7
17.4 11.1 14.2 14.5 14.1 14.5 ± 1.8
Fig. 8. Reciprocal changes of magnesium levels and VFI in relation to ﬁndings of stress
score.
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evident ﬂu.
3.10. Additional collateral clinical observations: liver function, tendinitis,
learn stress and side effects of supplementation with magnesium citrate
Since alteration in liver function parameters can be seen during ini-
tial phases of hyperthyroidism we followed-up 4 cases who presented
initially elevated levels of transaminases. Under the same supplementa-
tion regime with magnesium citrate and selenomethionine there was a
clear improvement of these parameters (Fig. 12). In two cases a rebound
increase of transaminaseswas seen at a timewhen the patients stopped
the supplementation.
A second important collateral ﬁnding was that of being able to im-
prove tendinitis complaints by using a neutral cream formulation to
which triiodothyronine (T3) was added. This empirical formulationwas developed on the basis of clinical ﬁndings in 4 patients who had
slightly elevated levels of fT3 in blood while presenting tendinitis.
Based on reports on the anti-inﬂammatory effects of thyroid hormones
on the skin [43–45] we designed a preparation containing 50 μg T3 in
25 ml of Ultrabas–Ultrasic. This approach was used in 29 patients
presenting complaints of tendinitis of the ﬂexor muscles of the arm as
well as in 1 case of epicondylitis. Such a situation can arise fromworking
on a computer and using a mouse on a relatively hyper-ﬂexed position
of the hand. Clinical improvement was seen in 29 cases within a
period of 2 to 4 weeks of using the cream 3 or more times per day.
The patient with epicondylitis showed no improvement and required
local use of steroids.
A group of 8 euthyroid subjects presenting anxiety and panic condi-
tion due to learn-stress at high school or university because of upcoming
important examinationswere treatedwith 4×1.4mmolmagnesiumcit-
rate daily. They reported feeling calmer and been able to learn better
within 10–14 days. This approach was conceived as a counter-measure
to magnesium loss under such situations [46].
Concerning side effects we can evaluate now more than 2000 indi-
vidual prescriptions of magnesium citrate over the last 2 years. We
have observed two single cases of loose stools which disappeared after
reducing the dose. Two subjects presented gastric hyperacidity.
4. Discussion
In this clinical study centered on patients with hyperthyroidism we
have been able to ﬁnd similar musculoskeletal changes and psycholog-
ical stress factors as those recently described by us in patients with hy-
pothyroidism [18]. Increasing levels of stressors are associated with
decreased levels of magnesium in blood whereby patients with hyper-
thyroidism have the lowest levels as compared with cases of hypothy-
roidism. Together with this biochemical alteration we document
increased levels of vascularity within the thyroid. Several stressors
such as psychological and physical, e.g. high level of sports achievement
in untrained subjects, as well as concurring infections had a negative in-
ﬂuence on thyroid vascularity, i.e. perfusion parameters increased. On
the therapeutic side we have demonstrated a beneﬁcial effect of a com-
bined supplementation regimen based on 200 μg of selenomethionine
and magnesium citrate 3 × 1.4 mmol/d over a period of 3 months on
thyroid function and on the intensity of thyroid vascularity. In view of
these results, the null-hypothesis of our study has to be discarded.
An important issue for patients has also been addressed by our
work: there was a clinical improvement in the well-being in themajor-
ity of cases after correcting the changes and deﬁcits these patients
presented. The patients reported feeling ﬁtter, having more energy,
showing less fatigue, constipation had disappeared, and they also re-
ported a better sleep quality. Single patients described less anxiety
and less panic attacks. We have continued to observe these positive
effects in patients that now consult us directly because of remaining
symptoms of thyroid disease in spite of being adequately treated,
medically speaking. This leads us to conclude that the clinical symptoms
in benign thyroid disease are not exclusively associated with thyroid
hormone levels but ratherwithmagnesiumdeﬁciency [18]. Magnesium
supplementation showed a beneﬁcial effect on thyroid economy lead-
ing to a normalization of TSH levels. These dualities in pathogenesis
have not been described before in thyroid practice and add a new in-
sight into thyroid physiology.
4.1. Implications that the biochemical mechanisms have for the observed
clinical ﬁndings
A central clinical issue of our study relates to the deﬁnition of normal
magnesium levels in blood. By having identiﬁedmusculoskeletal chang-
es and psychological stress as factors that lead to decreasedmagnesium
levels, the reference rangewas built on the basis of healthy controls that
lacked these stressors. We consider a reference range for magnesium of
Fig. 9. VFI values in relation to different stressors.
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cause it includes very low levels. Unfortunately for medical research a
considerable number of studies in the literature have worked with
such reference levels. In our opinion the reason for this large discrepan-
cy is that the deﬁnition of reference values for clinical chemical param-
eters did not include a detailed physical examination of the subjects.
Large number of anonymously obtained laboratory values cannot re-
place a clinical evaluation. In addition to this clinicians have to be
aware that magnesium intake has decreased in recent time [48] making
hypomagnesaemia maybe more probable and frequent. Finally studies
that have evaluated magnesium levels in different settings might have
to be re-appraised. Using a theoretical approach Liebscher and Liebscher
have provided an example of re-appraisal. They re-analyzed available
data on magnesium levels and concluded that adequate reference
values should have a lower limit of 0.9 mmol/l [49] which is close to
our calculatedmean reference value. On the therapeutical sidewe differ
from their point of view regarding the dose needed for substitution
given as 600 mg of magnesium daily. Unfortunately this publication
contains no details as to the exact formulation of the magnesium salt
that should be used. Additional discussion of this aspect is included in
Section 4.4.1.
4.2. Correlation between magnesium and selenium and hepatic function
It is interesting to remark that a positive correlation between whole
blood selenium and serummagnesium was lost in situations of thyroiddisease, sterility, depression and infection. This situation suggests that
blood magnesium levels seem to be related to an adequate selenium
uptake. An indirect hint can be found in the description of magnesium
saving action of the selenoprotein MsrB1 acting on TRPM6 [50]. On
the other hand, our preliminary data on improvement of hepatic
function parameters after supplementation coincides with the experi-
mental results reported by Markiewicz-Górka et al. [51]. The improve-
ment in liver function observed after supplementation in a small
group of patients is a novel ﬁnding in the ﬁeld of hepatology. In 1975
McConnell et al. described a lower Se content expressed in μg Se per
gram dry weight in patients with “diseased liver” [52]. In 1979 Sullivan
et al. described the concomitant ﬁnding of low levels of Mg and Se in
patients with cirrhosis [53]. Other authors also described decreased
levels of Se in alcoholic cirrhosis [54,55]. In an experimental model
presented by Li [56] an increased content of lipid peroxide and hydro-
peroxide were found in guinea pigs with selenium deﬁciency. In 1993
Rayssiguier et al. [57] described the inﬂuence of magnesium deﬁciency
to an increased level of peroxidation of lipoproteins. In 2001 Loguercio
et al. [58] found decreased levels of Se in relation with chronic liver
damage. Navarro Alarcón et al. [59] described a negative correlation
between Se and liver function parameters such as glutamic–
oxalacetic-transaminase and gamma-glutamic-transferase. In the ﬁeld
of oncological epidemiology Strasak et al. [60] described a relation
between elevated gamma-glutamic-transferase and cancer incidence
in women. These studies, however, have not developed any therapeutic
recommendations.
Fig. 10. Improvement of thyroid morphology and vascularization following 3 years of supplementation with selenomethionine and magnesium citrate as well after correcting lateral
tension and stress. Left pair initial situation, right pair follow-up after 3 years.
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Based on medical literature, we have previously hypothesized that
low magnesium levels could affect both ATP synthesis [61] as well as
telomerase activity [18]. The interaction of low levels of magnesium
with telomerase activity has been demonstrated recently in-vitro by
The Alturas and collaborators [62]. Our supplementation procedure
with magnesium citrate and selenomethionine thus gains importance
in awider context of clinical situations. In the ﬁrst place it could contrib-
ute to an improvement in the treatment of mitochondrial diseases,
where magnesium is often not even recalled in schematic representa-
tions of the function of Complex V of OXPHOS [63]. Clear-cut descrip-
tions of the importance of magnesium in relation to ATP can be found
in other recent publications [64–67]. Vinogradov has described the reg-
ulation of F1FOATPase and the role of magnesium [19]. The reaction of
mitochondrial H + -ATP synthase reads:
ADPþ Piþ nHþoutþmHþ→ATPþH2Oþ nHþin:
Mg
Further literature describes the interaction of magnesium on
F1F0ATPase [68] and the relation of magnesium to the nucleotide bind-
ing sites of F1F0ATPase [69].4.4. How new are our ﬁndings? Historical review on magnesium and
thyroid disease
The oldest report we have found that deals with the use of magne-
sium for treating hyperthyroidism was published by Hueber in 1939
[70]. The author based his approach on experimental observations rela-
tive to a down-regulation of cellular respiration of the cardiacmuscle of
the frog as well as to a slowing down of energetic processes. Hueber
treated 6 patients who presented tachycardia, increased perspiration,
weight loss, tendency towards being easily aroused, and tremor. All of
them had an elevated basal metabolic rate. In 2 cases the hyper meta-
bolic condition developed after an infection. The treatment consisted
in a t.i.d. administration of 1.5 g of magnesium glutaminate, either i.m.
or i.v., over three days. After this treatment the initial high values of
basal metabolic rate fell from 125–160% to 107–113%. The patients re-
ported a feeling of well-being and cardiac symptoms disappeared.
Only one female patient required a longer treatment. Due to persistence
of hyper-metabolism she was submitted to thyroid surgery. The histol-
ogy revealed a toxic adenoma. The results were explained in the light of
the work of Warburg on quantization of cell respiration [71,72].
In 1961 Wiswell studied the effects of 1.0 g magnesium sulfate, an
inorganic salt given b.i.d. to 2 patients with hyperthyroidism without
seeing beneﬁcial effects. One patient with hypothyroidism was treated
ﬁrst with 1.0 mg of triiodothyronine and then magnesium sulfate. The
author observed a marked rise in urinary excretion of magnesium. In
Fig. 11. Demonstration of decreased vascularization in a female patient with hyperthyroidism following supplementation with magnesium citrate and selenomethionine over a period of
14 months. coenzyme Q10 (120 mg/d) was added in the last 4 months.
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nesium chloride [73]. The dose given to 2 of his patients was 20 ml of
a 25% solution by deep intramuscular injection. The patients reported
that the injections were painful. The following patients were treated
successfully with magnesium chloride beginning with a 1% solution.
The dose was later increased to a 14% solution. The patients treated
this way showed an improvement of their symptoms while at the
same time goiter size was reduced.
4.4.1. How to choose an adequate magnesium salt for supplementation
Wewould like to stress the implicit differences of the pharmacolog-
ical preparations: good effects were observed by Hueber when using a
glutaminate, whereas Wiswell found no changes while working with
an anorganic salt, i.e. sulfate. This leads us to the question whether all
these approaches can be compared? While the use of supplementation
with magnesium to treat musculoskeletal changes has been rarely
described, several studies have looked at metabolic derangements.
Most published studies have used non-organic magnesium salts such
as sulfate or oxide. In 1982 Dyckner and Wester gave a general recom-
mendation as to administer 30 mmol of magnesium sulfate intrave-
nously over 12 h [74]. Oster and Epstein recommended magnesium
oxide up to 4 times 12.34 mmol [75]. Using magnesium pidolate,
Paolisso et al. administered 16.2 mmol to adult patients aiming at an
improvement of glucose handling [76]. Lima et al. administered either
20.7 or 41.7 mmol of magnesium oxide to patients with type 2 diabetes
[77]. Ayuk and Gittoes advocate the i.v. use of magnesium sulfate
starting with doses of 8 to 12 g (corresponds to 32.91 to 49.47 mmolmagnesium) [78]. It is clear that the doses of anorganic magnesium
salts are exceedingly higher than those of magnesium citrate. The read-
er should be aware of the beneﬁcial effects of magnesium citrate on en-
ergetics and the importance of the citrate transporter for mitochondrial
homeostasis [36,37,79]. This appears to us to be of central importance in
our study since hypothyroidism affects negatively the mitochondrial
citrate carrier activity [80].
The importance of citrate has been described by Icard, Poulain, and
Lincet recently [81]. In their publication they stress the functional
importance of citrate in mitochondrial function and also mention
that citrate “also acts as an “energy gauge”, a powerful sensor and
regulator of cell energy production, adjusting both production and
need” (page 115 in [81]). Citrate is an important carrier of acetyl groups
from the mitochondria to the cytoplasm [82]. The human sodium-
coupled citrate transporter has been described as an important player
in the generation of metabolic energy [83].
4.5. Magnesium and thyroid function
Besides these data on the therapeutic use of magnesium, informa-
tion on a relation between magnesium and thyroid function can be
found in publications which appeared some 60 years ago. Experiments
that aimed at interfering oxidative phosphorylation in thyroid samples
were conducted in 1955 by Freinkel and Ingbar [84,85]. Usingdisruptors
such as 2,4-dinitrophenol or cyanide the iodide concentrating capacity
of the thyroid was lowered. In 1968 Tyler et al. investigated the effect
of mitochondrial inhibitors on the energy-dependent uptake of iodide
Fig. 12. Beneﬁcial action of the supplementation on liver function tests.
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none lowered the tissue tomedium ratio of iodine, which reﬂects iodine
uptake, and inhibited also oxygen uptake. The tissue to medium ratio
fell from 38.1–45.5 in the controls to 2.8–3.2 for oligomycin, 1.6–2.2
for antimycin, and to 1.5 for rotenone. Using nucleotide determinations
they found a signiﬁcant drop of nucleoside triphosphate content in
thyroid slices when the inhibitors were used. They concluded that en-
dogenous ATP synthesis appeared to be essential for iodide uptake to
take place. While glycolytic ATP synthesis was able to provide energy
for iodide uptake, exogenous ATP had no effect. It should be kept in
mind that oligomycin is an inhibitor of Complex V of the respiratory
chain where ATP synthesis takes place [87]. In 1972 Heaton and
Humphray [88] observed under experimental conditions that the up-
take of radioactive iodine by thyroid glands depends on magnesium
sincemagnesium loading stimulated this process while magnesium de-
ﬁciency resulted in an inhibition of uptake. These effects would explain
the changes in TSH levelswhichwe found aftermagnesium supplemen-
tation. Surprisingly we observed no constant pattern of change for fT4.
Both hormones appear to have a complex interrelationship [89–91].
The role of magnesium in this context has not been investigated.
4.6. Thyroid function and oxidative phosphorylation
We would like to describe other studies that dealt with the relation
between thyroid function and oxidative phosphorylation and which ap-
peared in the time period 1951 to 1957. Some key ﬁndings were the
uncoupling of respiration and phosphorylation by thyroid hormones
[92,93] which was accompanied by swelling of the mitochondria [94]
while magnesium administration displayed an antagonistic effect [95].
In 1951 Carl Martius and Benno Hess measured phosphate esteriﬁcation
and demonstrated an inhibitory action for thyroxine [96]. This
effect resulted from the use of a pharmacological dose of the hormone,
i.e. 6 mg, for rats weighing approximately 120 g. This corresponds to
50 μg per gram. In 1954 Hoch and Lipmann published a study entitled“The uncoupling of respiration and phosphorylation by thyroid
hormones” [92]. The authors utilized tissues from animals that were arti-
ﬁcially made hyperthyroxinaemic. The animals used were young male
Syrian hamsters having a mean weight of 100 g. The dose used was of
4 mg in 0.5 ml on the ﬁrst day followed by 8 mg in the following 3 day
making a total dose of 28 mg in 4 days. This total dose corresponded to
280 μg per gram weight. It should be noted that in human medicine the
usual thyroxine substitution dose lies between 100–125 μg for a subject
weighing approximately 70 kg.
In 1962 two further papers appeared [97,98]. Hoch here discussed
the nature of thyrotoxicosis as being a disease of mitochondria. He rec-
ognized that the doses of thyroxine used in experimental settings are
quite high (page 447 in [98]). Referring to “… the paradoxical metabolic
and physical inefﬁciency of thyrotoxic subjects… suggests that thyro-
toxicosis is a disease of defective energy transfer” (page 448 in [97]).
In the discussion he describes the uncoupling of oxidation and
phosphorylation which results in inefﬁcient energy utilization. An
explanation was not given in the publication. In the second paper, he
discusses the fact that hyperthyroidism is associated with glycogen
depletion [97]. He also discusses the biochemistry of skeletal muscle
which depends upon oxidative re-synthesis of ATP for regeneration of
ATP. In a short discussion Hoch touches the topic of magnesium in
relation to OXPHOS and concludes that this area of investigation needs
to be clariﬁed.
Vitale et al. reported that thyroxine administration had an effect on
magnesium requirements, i.e. an increased demand [99], and that the
changes seen after administering thyroxine were similar to those seen
in conditions of magnesium deﬁciency [100]. Again the dose of thyrox-
ine used in these experiments was quite high, i.e. 1 to 4 mg per 100 g
diet. In those experiments where magnesium was administered, one
cannot exactly reconstruct how much elemental magnesiumwas actu-
ally given. OXPHOS was impaired in the thyroxine treated animals and
this change was repaired by magnesium supplementation. Weight
gain of the rats was maximal with 80 mg % magnesium and lowest
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well as thyroxine excess produced signs of magnesium deﬁciency in
the sense of vasodilatation and hyperemia [99]. In the experiments
with magnesium deﬁciency, cardiac muscle was more sensitive than
kidney and liver showing a decrease in OXPHOS. The injection of thy-
roxine also produced a fall in OXPHOS and this change could be
prevented by administering magnesium [100]. In view of these results
Vitale et al. proposed that hyperthyroidism leads to an increased mag-
nesium requirement.
In 1962Corradino et al. [101] summarized someof these early obser-
vations and concluded that magnesium may serve to regulate the thy-
roid function itself. In their own experimental work they found an
increase in the size of the thyroid under conditions of low magnesium.
In 1966 Jones et al. presented a review on the topic of magnesium levels
in relation to thyroid function [102]. In hyperthyroidism urinary
excretionwas elevated, and the oppositewas found in cases of hypothy-
roidism. Treatment of the corresponding thyroid diseases normalized
the excretion values. It is interesting to recall that they observed a
higher excretion rate of magnesiumbeing achieved by T3, which is sim-
ilar to the effect recently described by Rodrigues Dare [103]. In 1968
Hoch stated the reciprocal relation between thyroid hormones and
magnesium as follows: “Magnesium metabolism depends upon the
thyroid state, and vice versa. Mg++ and thyroid hormones are antago-
nists in vivo and in vitro when mitochondrial function is measured”
(page 357 in [104]). In 1996 Disashi et al. described a negative
correlation between fT3 and Mg [105]. These details and our ﬁndings
indicate that current concepts on thyroid hormone action might have
to be re-evaluated [106].
4.7. Development and expansion of the WOMED model: the pathway to an
acquired alteration of mitochondrial function affecting Complex V of
oxidative phosphorylation
4.7.1. Ankle sprain grade I as the trigger
We postulate that the chain of events involved in the development
of thyroid disease begins with an ankle sprain grade I lesion. Since this
slight lesion does not require medical intervention not all patients can
immediately recall such an event, thus this information can be tempo-
rarily lost. Having a grade I ankle sprain bodyweight is shifted to the un-
affected body side.We have called this situation lateral tension [10].We
have been the ﬁrst authors to describe these changes and have a com-
plete follow-up of the index patient. The affected limb assumes an
eccentric muscle position with an outward rotation of the leg and an
anteriorly rotated iliac spine. This lateral tension affects the shank
muscles, i.e. the triceps surae and the soleus, a muscle group that has
a special meaning in body support [107,108] thus being challenged
every day in its anti-gravity function. Both the soleus and gastrocnemius
muscles are involved in producing ballistic bias impulses in relation to
human postural sway [109]. The amount of muscle activity during the
day can vary according to its intensity [110]. This challenge is not of
great daily magnitude per se, however the muscular consequences
add up through time. We have seen that the time at which ankle supi-
nation lesions occurred was longer than 5–10 years. Our evaluation of
body weight distribution shows a slight displacement of 2–3% of body
weight away from the affected side. For a person with 70 kg body
weight this would correspond to adding 1.4 to 2.1 kg of weight to the
unaffected side. The ensuing bioenergetics of such a body shift has
have been described elsewhere by us [18]. Adding a similar amount of
weight to a limb will result in an increased metabolic rate [111,112].
In short form there is higher energy expenditure and themain resulting
symptom can be fatigue which becomes one of the main complaints of
the patients.
Two interesting aspects of ankle sprain have been described in a re-
cent publicationmade by the International Ankle Consortium [113]. The
ﬁrst one refers to the lack of medical care in the majority of cases; the
second one describes the long term sequelae calling them a largehealthcare burden. We ﬁrmly believe that our approach could help to
improve outcome. We have found no studies that looked at thyroid
function following ankle sprain [114–116].
In addition to lateral tension the coordinated movement of the dia-
phragm and pelvis [117] can be affected due to a blocked pelvic move-
ment in the inspiration phase due to a backward tilted pelvis. Although
we have not found any biomechanical investigation on this topic it is
logical to consider this backward tilt as a condition that increases the
physiological angle between the pelvis and the legs, i.e. stretching, and
might be contributing factor for the development of IMT. Both lateral
tension and IMT are associated with low levels of magnesium. IMT can
be corrected by magnesium supplementation alone in a great number
of patients. Treatment of lateral tension requires manual medicine pro-
cedures and acupuncture.
Besides these biomechanical elements one also has to consider local
changes after the supination lesion. The initial lesion induces a ﬂexion–
supination stretching of the shank muscles putting strain on the bony
insertions sites resulting in muscle tear. This tear lesion is associated
with micro-hemorrhages that can be found after using acupuncture at
the site of the lesion [118]. The constant eccentric muscle action during
every day activities could add through the yearsmore shear stress to the
shank. This event can be viewed to be similar to crush muscle injuries
where pressure- stretch changes occur. Ionic ﬂuxes activate energy-
dependent mechanisms — which will require inevitably magnesium.
A depletion of ATP will follow [119]. Local perfusion is increased in
such lesions [120] by which signal molecules will be transported
systemically.
This local event activates the danger elements in front of an anatomi-
cal lesion and will also have as a consequence a stimulation of the
immune system as can be demonstrated under experimental condi-
tions [121] or in the context of the “danger theory” put forward by Polly
Matzinger. One key concept in this theory is that cellular alarm signals
arise endogenously fromdistressed or injured cells [122,123]. This species
of molecules are called damage associated molecular pattern (DAMP)
molecules which undergo denaturation once they are released from the
affected cell [124]. According to our model, we would expect that the
local inﬂuence of injury will be then followed by mitochondrial distress.
Mitochondria in distress could turn to be sources of inﬂammatory signals
[125]. Additional signals that could be released from the lesion include
myoglobin. Myoglobin levels have been described as being altered in
cases of thyroid disease [126,127]. Myoglobin has been detected also in
thyroid tissue [128,129]. Patients with thyroid diseases can have
anti-myoglobin antibodies in blood [128,130].
4.7.2. Anxiety, cognition, telomerase activity and the role of
psychological stress
A further central issue involved in this complex is psychological
stress which needs to be identiﬁed and treated. While we focus our
discussion on thyroid disease recent data has pointed out the effect of
adversities in early life which inﬂuence physiological regulation in
later life [131]. While the original theories of Selye on the general adap-
tation syndrome as a response to a general alarm reaction [132] initiat-
ed research on the hormones of the HPA, recent experimental research
has clearly demonstrated the endocrine response pattern associated
with stress reactions can be triggered by a condition of magnesium
deﬁciency. This leads to a situation of anxiety and to activation of the
HPA axis [133]. Altogether we believe that is sensible to propose that
as a consequence of the negative effects of the physical and psycholog-
ical stressors magnesium levels decrease creating a situation which
increases the general susceptibility to stress [134]. On the other hand
and contrastingwith chronic stressors, acute stress has been considered
to be beneﬁcial as it stimulates neurogenesis in the hippocampus under
experimental conditions [135].
Cognitive impairments and fear generalization have some common
elements that are linked to magnesium, selenium and coenzyme Q10
as well as to the hippocampus. In order to describe these links we cite
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corresponds roughly to life development. The main terms describing
this setting are maternal prenatal stress and early life stress. In a similar
way research on epigenetics goes even to consider a broader time win-
dow. Citing Lo and Zhou [136]: “There are three categorical stages of life
historywhen epigenetics are registered— ancestral (including parents),
prenatal, and postnatal stages. Among these stages, prenatal epigenetic
registration is the most eminent and profound inﬂuence on the forma-
tion or ﬁne-tuning of the nervous system during development.” We
consider that the starting point in clinical work should consider prenatal
maternal stress which can be seen as a contributing factor to stress con-
duct later in life [137–139]. These effects show changes in the function
of the hippocampus [140]. Early life stress has been found to shape
areas of the brain related to emotion processing located on the hippo-
campus and amygdala [141] and early life stress can be related to hippo-
campal cell loss [142] as well as to inhibition of neurogenesis [143]. The
timing of these situations, i.e. pregnancy [144], is directly related to the
concept of pre-natal stress. Ante-natal stress has also been considered as
a possible origin of later psychopathology [28,145]. Both intellectual
functioning and cognitive ability or development can be affected in chil-
dren [146–150]. Contrary to pre-natal stress, maternal care promotes
hippocampal synaptogenesis and in the end cognitive development
[151]. This function is related to the brain-derived neurotrophic factor
(BDNF). Selenium exerts neuroprotective action on the hippocampus
in relation to BDNF [152]. One important mechanism that is found in
cases ofmaltreatment is DNAmethylation of BDNF [153]. Szyf considers
DNAmethylation amechanismbywhich experiences in early life can be
embedded [154,155]. Experimentalmagnesium deﬁciency during preg-
nancy has been found to be related to hyper-methylation [156]. An ad-
ditional mechanism related to intrauterine stress is the appearance of
shorter telomeres in young adults [157]. The Alturas have recently dem-
onstrated that short-termmagnesiumdeﬁciency can down regulate tel-
omerase [62]. In addition to this, Bachnas et al. have shown that
antenatal supplementation with magnesium sulfate in humans can im-
prove the levels of BDNF [158]. In the setting of experimental meno-
pause, Sandhir et al. have found that coenzyme Q10 can ameliorate
cognitive functions [159]. Low selenium levels in elderly people can be
associated with cognitive decline [160]. Exciting experimental data
have been recently presented by Abumaria et al. on the beneﬁcial effect
of magnesium supplementation using a new compound magnesium L-
threonate. It is effective in preventing fear over-generalization [161]
and it can also enhance the retention of the extinction of fear memory
[162]. Wang et al. have observed that magnesium L-threonate can pre-
vent and restore memory deﬁcits related to neuropathic pain involving
TNF-alpha [163]. Cognitive functions such as learning can also be posi-
tivelymodulated bymagnesium administration. This last action is relat-
ed (again) to changes in the hippocampus [164]. These experimental
ﬁndings are of interest to our research because they correlate with the
effects of thyroid function on the hippocampus [165–168] as well as
to psychological stress due to trauma [46,134,169,170]. As a corollary
of these data we propose that magnesium deﬁciency could be involved
in altered cognition development, an issue that has been seen almost
exclusively to be related to thyroid function. An additional aspect to
be kept in mind is the pattern of brain metabolism: synaptic growth
gene expression is related to aerobic glycolysis while synaptic transmis-
sion is related to oxidative glycolysis [171]. Age differences in the met-
abolic patterns in the brain are apparent [172], thus injuries occurring
at different ages might have other sequels.
4.7.3. Magnesium, energetics and the immune system
Our observation of altered thyroid perfusion in relation to concur-
ring infection made us curious about the energetic aspects of the im-
mune system. The ﬁne tuning of T-cell function and energetics has
been summarized by Pearce et al. recently [173]. Magnesium even as-
sumes the role of a second messenger that couples receptor activation
[174] and is also involved in cytotoxic functions of NK cells [175].Proliferative transition in lymphocytes are regulated by TRPM7 [176].
In 1994 Meldrun, Ayala and Chaudry described that administering
ATP-MgCl2 led to improved lymphocyte energetics in late sepsis [177].
Both TRPM6 and TRPM7 are closely related to magnesium metabolism
[178,179]. On the side of pathogens, their spreading is also an energy
consumingprocess [180]. According to Straub the chronicity in an infec-
tious situation will occur when energetic reserves of the organism have
been consumed [181,182]. One has to view this consumption as part of
the energetic demands which are needed for the immune response. In
view of these modern data, it is not surprising that hyperthyroidism
could develop following an infection as was described by Hueber [70].
These processes could explain the generally known symptomofmalaise
that is associated with viral infections. It follows that adequate magne-
sium levels are necessary for themaintenance of a well-functioning im-
mune system.
4.7.4. Mitochondrial function and physical ﬁtness
Some modern studies have also investigated the relation between
hypothyroidism and mitochondrial function. Siciliano et al. found an
altered mitochondrial respiratory function in patients with hypothy-
roidism [183]. Although the authors described the presence ofmusculo-
skeletal symptoms as being related to the legs they examined biopsy
samples taken from the left deltoid muscle. Analysis of muscle samples
revealed a decrease in cytochrome c oxidase activity as well as a reduc-
tion in the levels of mitochondrial transcription factor A. In a later study
they described the lack of effect of treatment with levothyroxine on
muscle function in patients with hypothyroidism. Their study relied
on parameters such as glucose tolerance, insulin response to glucose,
resting heart rate, resting andmaximal VO2, andmaximal power output
[184]. Contrary to the philosophy of ourWOMEDmodel approach,mus-
culoskeletal symptoms were collected by a questionnaire, i.e. by means
of hands-never-on the patient. We feel that a simple manual examina-
tion is imperative in this type of studies. A similar situation of hands-
never-on the patient can be found in the ﬁeld of sports medicine. In
one study elite athletes attempted to get a satisfactory answer for
their tiredness and recorded their answers on questionnaires [185]. A
high level international consensus report on how to approach the
over-training syndrome discarded a-priori the importance of magne-
sium levels [186]. It is known, however, that strenuous exercise will
exert a negative inﬂuence on magnesium levels [187].
4.7.5. Muscular damage and muscle repair: the role of thyroid hormones
What puts skeletal muscles and thyroid together? In relation to thy-
roid function, one has to differentiate two conditions: hypo- and hyper-
thyroidism. Low levels of magnesium could impair the capacity of the
thyroid to import iodine actively thus leading to hypothyroidism. On
the other hand, patients with hyperthyroidism present more musculo-
skeletal alterations due to altered axial orientation of the body [8,9]
which will consequently demand more repair mechanisms. Muscle re-
pair belongs to the scope of action of thyroid hormone [188–191]. In ad-
dition seleniumdeﬁciency can affect the concentration of this substance
inmuscular tissue [192].We propose that the loadofmusclemass need-
ing repair will put a higher physiological demand on the level of thyroid
hormone production [193–195] leading to a hyperthyroid state. This
demand has to be met in an environment of selenium deﬁciency [11]
and knowing that selenoproteins are important for skeletal muscle
[196,197] muscle repair might also suffer from selenium deﬁciency.
Due to seleniumdeﬁciency the action of deiodinases canbe lowat the tis-
sue level thus “forcing” the thyroid to produce a hyperthyroid state that
produces preferentially triiodothyronine. Experimental data show clearly
the effects of T3 in the maturation of muscle satellite cells [195]. In this
system the differentiating muscle satellite cells produce FOXO3 which
then stimulates the synthesis of deiodinase II [193]. Levels of deiodinase
II are higher in slow twitchmuscle cells [198]. Looking at the depiction of
this process in a recent review [195] it is fundamental to add the fact that
in turn FOXO3 is activated by AMP kinase (AMPK) [199]. AMPK functions
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add the notion that ATP levels diminish when magnesium levels are
low. In addition to this, selenium intervenes again in this system adding
a stimulatory action by activating AMPK as seen in experimental data
from colon Ca cells [201]. In order to have physiological effects of
selenium, it is important that hepatocytes maintain a good functional
level in order to produce selenoprotein P [202]. Sepp1 needs to be in
the long form, i.e. containing more than 6 Se-cysteine moieties, in order
to be taken into the cells via the ApoER2 receptor [203,204]. As we
have shown in a small group of patients, supplementation with
selenomethionine andmagnesiumcan lead to improved hepatic function
thus potentially inﬂuencing selenoprotein P synthesis. Another interest-
ing fact is that FOXO3 is also involved in the regulation of mitochondrial
function [205], thus bringing us back to the site of oxidative phosphory-
lation. De Lorgeril and Salen have discussed the importance of a function-
ing deiodinase system in order to achieve myocardial repair [206]. This
action should also apply to skeletal muscle. Magnesium deﬁciency can
also affect myogenesis [207].
One important issue to keep onmind is the need ofmitochondrial bio-
genesiswith increased citrate synthase activity formuscle regeneration to
occur [208] (please refer to Section 4.4.1 on the choice of an adequate
magnesium salt for supplementation). In turn thyroid hormones are
effective on mitochondrial biogenesis as well as on muscle repair
[209–211].
4.7.6. Hypothesis: thyroid disease as an acquired dysfunction of
mitochondrial function
Contrasting with genetically determined mitochondrial disease we
propose that thyroid disease is amitochondrial dysfunction entity relat-
ed to an acquired condition of magnesium deﬁciency. Low levels of
magnesium will produce an uncoupling of oxidative phosphorylation
which is potentiated in cases of hyperthyroidism. All of these mecha-
nisms compromise the function of the respiratory complex V leading
to a decrease of the energetic capacity of the body.
Additional negative contributions can be due to low levels of
coenzyme Q10 which in turn can be the result of low selenium levels
[212,213]. An additional factor which we have observed is increased
vascularity under oral contraceptives. These pharmaceuticals have
been found to inﬂuence negatively coenzyme Q10 levels [214–216].
Low selenium levels can also compromise mitochondrial biogenesis
[217,218]. In turn the selenoprotein thioredoxin reductase is an essen-
tial element that reduces coenzyme Q10 [219,220]. In a neuronal
model of coenzyme Q10 deﬁciency a reversal of ATP synthase activity
was observed [221]. On the therapeutical side coenzyme Q10 can inﬂu-
ence positively mitochondrial function [222], as well as angiogenesis
and endothelium function [223–225]. This action on angiogenesis is
said to be due to an interaction with ﬁbroblast growth factor. Indepen-
dent studies donewith thyroid tissue have indeed shown this combina-
tion of ﬁndings: low levels of coenzymeQ10 [226] and elevated levels of
FGF [227]. Our studies can be seen as a demonstration of the role of
magnesium, selenium and coenzyme Q10 in vascularity. Recently,
Kharitonova et al. have shown a beneﬁcial effect of magnesium supple-
mentation in restoring endothelial function [228]. It follows that the
combined use of coenzyme Q10 and magnesium can be seen as an
instrument to approach vascular disease. On the other hand, the
hypothesis that thyroid hormones alone regulate vascularity, as
discussed by some authors [229], has to be taken with caution since
the data come frequently from in-vitro models that have used very
high doses of thyroxine. One early work onmyocardial hypertrophy fol-
lowing thyroxine administration utilized a dose of 250 μg/kg body
weight s.c. per day. According to data from the RGD and data from
Kurtz and Morris [230], the mean weight at 13 weeks would be 242
and 174 g for male and female rats, respectively. Using these ﬁgures the
daily dose of thyroxine would be 60 μg and corresponds almost to the
daily dose an adult person would need (dose app. 1 μg/kg body weight).
Recently Freitas et al. have reported changes in the myocardium utilizinga high dose of thyroxine (600 μg/kg/day which corresponds to 150 μg/d
per animal having a weight of 250 g). An extrapolation of these results
to any human condition is not conceivable on physiological terms [231].
The same applies to the studies on thyroid hormones and oxidative
phosphorylation (Section 4.6).
4.7.7. Shortcomings found in studies on mitochondrial disease
A systematic shortcoming on the description of oxidative phosphor-
ylation is the avoidance of magnesium in the description of OXPHOS.
Few publications can be found that deal explicitly with Complex V
[232]. Quoting De Los Rios Castillo: “The oxidative system (respiratory
chain) couples redox reactions to the production of a proton electro-
chemical gradient, which drives the synthesis of ATP by the phosphory-
lation system (FOF1-ATP synthase and theADP andphosphate carriers)”.
It has been suggested that the presence of cristae in mitochondria de-
pends on the ability of complex V to form dimers [233]. On the other
hand, lack of magnesium will result in mitochondrial swelling. Magne-
sium deﬁciency is also related to an altered cellular composition such
as a decreased number ofmitochondria.Magnesium restoresmitochon-
drial membrane potential [234]. Beard has described a biophysical
model of the respiratory system of the mitochondria. On page 0255 he
describes the ﬂuxes involved in magnesium binding (Eq. 12 in [235]).
Few studies have documented changes in mitochondria in relation to
thyroid disease. Hypothyroid myopathy has been found to show ab-
sence ofmitochondria [236]. A case ofmyopathy in relationwith seleni-
um deﬁciencywas described as being associatedwithmuscle weakness
[237]. Recently interest onmitochondrial function has been described in
the ﬁeld of infertility [238]. Bloom et al. have shown that fecundity is re-
lated to magnesium levels [239]. This topic remains to be investigated.
4.7.8. A short corollary on thyroid disease and magnesium
Elaborating on the experimental data mentioned in the discussion
we propose the hypothesis that thyroid function is related to magne-
sium availability. Lack of magnesium will affect iodine transport which
depends on energy delivered by magnesium-ATP resulting in hypothy-
roidism. Due to the larger burden due to musculoskeletal changes in
cases of hyperthyroidism magnesium levels are lower and there is a
preferential increase of triiodothyronine. This increase is tailored to re-
generate slow twitch muscles [210]. In patients with hyperthyroidism
the T3/T4 ratio is indeed altered [240] and hyperthyroid patients with
a high T3/T4 ratio are prone to have a relapse [241]. Iodine metabolism
in these patients is increased [242]. At a ﬁnal stage the lack of magne-
sium could affect the function of Complex V of OXPHOS causing symp-
toms that have been traditionally assigned to thyroid dysfunction.
4.8. A comment on animal models of thyroid disease
For many years the model of active immunization with thyroglobu-
lin has been considered to show a relation to human disease. These his-
torical experiments aimed at the induction of thyroglobulin antibodies
using organ extracts from different species together with adjuvants
such as toluene, heat-killed acid fast bacteria (Dr. Jules Freund, NY),
melted lanolin, mineral oil (Bayol F2, Esso Reﬁning Co.), and a
monooleate of manitol (Arlacel, Atlas Powder Co. ®) [243]. Another
model that has been investigated in the past is that of thyroiditis in
the obese strain of chickens. Following the original description of iodin-
ation of casein [244] a similar product (Protamone ®) was used in the
basic diet of these birds. This casein preparation aimed at introducing
a series of active thyroid hormone components. Within the extensive
description of the patent for this product one can ﬁnd the statement
on the need to have magnesium included in order to increase the met-
abolic rate (e.g. paragraph 053 in [245]). This aspect is seldom men-
tioned later in publications dealing with this model. We found no
publication dealing with magnesium and the obese strain of chickens.
In the ﬁeld of poultry research Hajj and Sell described the need of mag-
nesium in order tomaintain oxidative phosphorylation in the layinghen
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aspartate supplementation on the levels of thyroid hormones in broilers
[247]. These authors even suggested the possibility of usingmagnesium
supplementation in the obese/obese model. This suggestion was never
explored. We had the opportunity to examine a small series of the last
available animals of the obese strain of chickens at the Medical
University of Innsbruck. This evaluation was done together with Dr. H.
Dietrich and Dr. H. Talasz (Innsbruck) and Prof. Lutz Schomburg
(Berlin). The chickens presented high levels of selenium in blood
while liver selenoproteins were low. This picture suggests a defect in
selenium utilization or transport (unpublished data from 2007) as
well as a potential defect in selenoprotein synthesis. Alterations in
selenium economy can be associated with changes in the immune
system [248,249]. In addition to this a modulation of gene expression
proﬁles of Complex I, IV and V has been observed following administra-
tion of selenium [250].
We ﬁrmly believe that the central requirement for an animal model
that attempts to reproduce our ﬁndings should be to include the
characteristic of bipedalism; otherwise the interaction of the gastrocne-
mius and soleusmuscles in their anti-gravitational function after having
had a supination lesion will not be present. Due to similarities of the
shank muscles in primates with bipedal postures similar alterations
could be produced and have a close resemblance to our model [251].
Generally speaking, however, hyperthyroidism has not been described
in great apes [252]. In any case one should not forget that the general
transferability of animal experiments has to be taken with caution
[253]. Clinical research of human conditions is still the golden standard
for us.
4.9. A comment on the uncertainty of clinical research
Our study describes a new examination and treatment approach as
well as a new explanation of benign, non-nodular thyroid disease.
Although muscular changes have been observed in some cases of pa-
tients with thyroid disease, similar data that relate these events tomag-
nesium cannot be found in the literature. The same applies to the role of
psychological stress. This maybe uneasy situation will awaken the
philosophical urge of the critical reader to either accept or reject our
hypothesis. For this reason we will add here some notions encountered
in literature that deal with the philosophy of research.
The ﬁrst setting relates to the Polish School of Philosophy of Medi-
cine which was founded by Tytus Chałubiński (1820–1889).1
Paraphrasing Stempsey's description [254] of the central approach
taken by Chałubiński one can extract that he “proposed a method of
ﬁnding proper therapy based on a holistic view ofmedicine and a vision
of disease as disturbed function.” In our study the disturbed function is
found in themusculoskeletal system.A second critical look at our results
is to askwhether themethodology is plausible.We believe that modern
science where genetics and “omics” are seen as indispensable tools, the
simple biomechanical function will be overlooked. This is intrinsically
related to the process of medical search of the most adequate method.
Again in the words of Stempsey [255]: “Clinicians use many strategies
and heuristics in order to formulate and test hypotheses and to draw in-
ferences from myriad clinical data”. It follows that research will only
achieve an approximation to the truth of disease. The complex situation
of causality can also be read in the paper fromBarata [256]: “Oestudoda
causalidade, portanto, diz respeito às relações de causa e efeito entre
fenômenos”. This statement puts the investigation of causality into the
setting of a relation between cause and effect. In our study patients
withmusculoskeletal changes have low levels of magnesium and a sim-
ilar situation applies to psychological stressors. Finally, in a modern1 “Starsza” polska szkoła ﬁlozoﬁi medycyny
http://pl.wikipedia.org/wiki/Polska_szko%C5%82a_ﬁlozoﬁi_medycyny.comment on the original work of Popper [257], Banegas et al. [258] con-
tribute the following statement: “What we actually do is to propose a
hypothesis as a tentative solution to a problem, to confront the predic-
tion deduced from the hypothesis with actual experience, and evaluate
whether the hypothesis is rejected or not by the facts.”
Considering these philosophical statements as requirements we be-
lieve that our study is within these lines as it describes mechanisms of
disturbed function as well as the therapeutical approach to treat them
and demonstrating clear effects on thyroid vascularization.
Study design and interpretation is an issue of lively debate. We
would like to add the following quote from Albert Szent-Györgyi
which we believe reﬂects the essence and value of observational stud-
ies: “Discovery consists of seeingwhat everybody has seen and thinking
what nobody has thought”.2
5. Conclusions
Our observational study has shown that both thyroid vascularity as
well as TSH levels are related to magnesium levels in blood. In turn
low magnesium levels are related to musculoskeletal changes as well
as to psychological stressors. These stressors show also a relationship
to vascularity. The quantitative 3D power Doppler sonography method
allows the differentiation of perfusion quality and quantity in the thy-
roid gland and is essential for monitoring the effects of supplementa-
tion. The novel endocrine effect of magnesium on TSH could occur by
improving iodine uptake, which is an energy-dependent process.
Clinical symptoms of patientswith thyroid disease can improve after
correction these three central elements: the musculoskeletal changes,
the effects of psychological stress, and the condition of magnesium
and selenium deﬁciency. Since the patients described here developed
signs of thyroid disease in adult age this condition can only be the result
of an acquired defect.We propose that themost likely site of interaction
is on Complex V of oxidative phosphorylation. In some cases coenzyme
Q10 deﬁciency can also play a role. Supplementation with magnesium
citrate and coenzyme Q10 appear to be beneﬁcial in reversing vascular
changes.
Since both hypo- and hyperthyroidism share the same selenium and
magnesium deﬁciencies we believe that the differentiating condition
leading to hyperthyroidism is that of a greater musculoskeletal alter-
ation. The ﬁnal clinical settingswould be: 1) Hypothyroidism: lowmag-
nesium levels with low iodine uptake and low need of muscle repair.
2) Hyperthyroidism: low magnesium together with inefﬁcient
OXPHOS and an increased need of muscle repair due to pronounced
musculoskeletal changes such as lateral tension and IMT. This condition
leads to increased production of thyroid hormones triiodothyronine
(preferentially) and thyroxine in order to induce muscle repair. Fig. 13




VFI vascularization and ﬂow index
TRPM transient receptor potential melastatin
IVF in vitro-fertilization
TAO thyroid associated ophthalmopathy
AK Applied Kinesiology
TCM Traditional Chinese Medicine
OXPHOS oxidative phosphorylation2 http://thinkexist.com/quotes/albert_szent-gyorgyi/.
Fig. 13. The basic elements iodine, selenium andmagnesiumare provided by an adequate nutrition and a healthy functioningGI tract. Magnesium is directly related tomagnesium–ATP in
Complex V of the ATP-some in the mitochondria. With sufﬁcient magnesium supply the mitochondria supply enough ATP and energy-dependent processes such as iodine uptake are
maintained. Selenium and selenoproteins play an important role in antioxidant functions in the body. Through the inﬂuence of physical and psychological stressors the balance of mag-
nesium availability can be compromised leading to diminished ATP production. Physical stress augments according to the intensity of physical activity. Thyroid hormones stimulate mi-
tochondrial biogenesis as well as muscle repair. The ﬁnal clinical settings are: 1) Hypothyroidism: low magnesium levels with low iodine uptake and low need of muscle repair.
2) Hyperthyroidism: lowmagnesiumwith inefﬁcient OXPHOS, increased need ofmuscle repair due tomusculoskeletal changes (lateral tension, IMT)which leads to increased production
of thyroid hormones triiodothyronine (preferentially) and thyroxine.
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Highlights: What was already known on this topic?
• Obscure origin of benign non-nodular thyroid disease.
• Some functional relationships between the musculoskeletal system
and the thyroid.
• Magnesium is required for iodine uptake in the thyroid.
What this study adds
• Deﬁnition of normal levels of magnesium in normal subjects as
N0.95 mmol/l.
• Normalization of TSH levels after Mg supplementation.
• 3D-perfusion patterns of the thyroid are responsive to supplemen-
tation with magnesium citrate and in some cases together with
coenzyme Q10.
• Reversibility of morphological changes in the thyroid after
supplementation.• Description of additional conditions associated with increased
thyroid perfusion such as psychological stress, physical stress,
infection.
• Need to treat psychological and physical stress in order to reduce
magnesium needs.
• Increased thyroid perfusion in the ﬁrst days after in-vitro fertiliza-
tion and egg transfer.
• Potential of detecting cases of coenzyme Q10 deﬁciency based on
the vascularization index and relation of vascularity to oral contra-
ceptives.
• The WOMED model as holistic clinical tool than can be applied
successfully.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbacli.2014.11.002.
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